A multicenter, retrospective study of patients with LBCL assessed in real time with a commercially available, immunoglobulin rearrangement-targeted ctDNA-MRD assay (clonoSEQM), finding post-treatment MRD after immunochemotherapy or chimeric antigen receptor T-cell (CAR-T) therapy was 15% versus 85% for detectable versus undetectable MRD.
Abstract
Measurable residual disease (MRD) analysis using circulating tumor DNA (ctDNA) is a non-invasive method of response assessment in large B-cell lymphoma (LBCL), but data supporting its real-world feasibility and performance are needed. We conducted a multicenter, retrospective study of patients with LBCL assessed in real time with a commercially available, immunoglobulin rearrangement-targeted ctDNA-MRD assay (clonoSEQM). Our primary objective was to assess post-treatment MRD after immunochemotherapy or chimeric antigen receptor T-cell (CAR-T) therapy. Median time from sample collection to MRD result was 9 days. Following frontline treatment (N=102), 12-month progression-free survival (PFS) was 15% versus 85% for detectable versus undetectable MRD (HR 14.5, p.
It is demonstrated that ctDNA could potentially be used for prognostication and disease monitoring in PTLD, outperforming PET/CT in 8 cases, indicating that ctDNA monitoring can complement PET/CT to guide early escalation to chemotherapy in high-risk patients, though larger cohorts are needed to validate these findings...
Y. Zhong, Nick Veltmaat, Filipe Montes de Jesus et al.· Blood Advances· 0 citations
Simple Summary B-cell maturation antigen (BCMA)-directed therapies (BDT) are approved for the treatment of relapsed/refractory multiple myeloma (RRMM). Several treatment modalities exist including chimeric antigen receptor T-cell therapy (CAR-T), bispecific antibodies (BsAbs), and antibody-drug conjugates (ADC). The ef...
Osama M. Younis, Sencer Goklemez, Carmel Awadallah et al.· Cancers· 0 citations
Early identification of refractory disease remains a significant unmet clinical need in patients with diffuse large B‐cell lymphoma (DLBCL). This scoping review was conducted to assess the current knowledge on the use of circulating tumor DNA (ctDNA), either alone or in combination with immune markers, as predictive to...
A. McMahon, E. Ryan, Sarah Dillon et al.· Hematological Oncology· 0 citations
High baseline circulating and tumor γδ T cells and early circulating CD8⁺PD-1⁺ T Cell expansion were associated with better outcome under AtezoBev, and an early induction of T cell-associated interferon-γ signaling at 3 weeks after the first injection of AtezoBev in patients that experienced response.
I. Galy-Fauroux, A. Asif-Laidin, M. Evain et al.· Clinical Cancer Research· 0 citations
Findings indicate that IL-17 may be a potential biomarker with stage-specific clinical associations in B-NHL and warrants further investigation for risk stratification and individualized treatment monitoring.
Xinlu Jiang, Xiao-Yu Wang, Li Yan et al.· Cytokine· 0 citations
Liquid biopsy guided anti-EGFR rechallenge therapy is gaining ground as a potential option for patient with refractory metastatic colorectal cancer. However, the identification of potential biomarkers to implement patient's stratification is required. The CAVE-2 GOIM trial investigated the role of rechallenge with cetu...
Davide Ciardiello, G. Martini, L. Boscolo Bielo et al.· The journal of liquid biopsy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.